Scope and Claims of US Patent 8,372,828
US Patent 8,372,828, granted on February 12, 2013, to Gilead Sciences, Inc., covers a novel class of hepatitis C virus (HCV) NS5A inhibitors. The patent primarily claims compounds characterized by specific chemical structures, methods of synthesizing these compounds, and their use in treating HCV infections.
Key Claims Overview
The patent contains 30 claims. The main independent claims define a chemical compound of a general structure with specific substituents, as well as pharmaceutical compositions containing these compounds.
Independent Claims:
-
Claim 1: A compound with a chemical structure described by Formula I, where substituents R1, R2, R3, and R4 are selected from specific groups (e.g., hydrogen, methyl, ethyl, etc.). The claim specifies the scope of substituents that can define the compound’s chemical framework.
-
Claim 20: A method of treating hepatitis C virus infection by administering an effective amount of a compound according to claim 1.
-
Claim 25: A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.
Dependent Claims:
Dependent claims narrow the scope by specifying particular substituents, stereochemistry, salt forms, and methods of synthesis.
Chemical Scope
The structure of compounds claimed resembles the class of piperazine derivatives with substitutions at specified positions, targeting NS5A, a viral protein critical for HCV replication. Key features include:
- Variability at R1-R4 substituents to optimize activity.
- Focus on bioavailability and pharmacokinetics.
- Salt forms and polymorphs to improve stability.
Patent Term and Jurisdiction
The filing date was May 2, 2012, with a prioritization claim from a PCT application. The patent is enforceable until 2032, assuming maintenance fees are paid. It has also been filed or granted in multiple jurisdictions, including Europe and Japan.
Patent Landscape Analysis
Global Patent Portfolio
Gilead Sciences has built a robust patent family around HCV protease and NS5A inhibitors. Key related patents include:
| Patent Number |
Title |
Filing Date |
Expiration Date |
Scope |
| US 8,372,828 |
NS5A inhibitors |
May 2, 2012 |
2032 |
Core chemical class, treatment methods |
| US 9,670,600 |
Combination therapies |
June 21, 2016 |
2036 |
Combination of NS5A inhibitors with other antivirals |
| EP 2807893 |
European counterpart |
July 2, 2014 |
2034 |
Variations of compound structures |
Competitive Landscape
- Major Patent Holders: Gilead Sciences, AbbVie, Merck, and Bristol-Myers Squibb hold patents covering various HCV NS5A inhibitors.
- Innovator's Position: Gilead’s Harvoni (ledipasvir + sofosbuvir) and Epclusa (sofosbuvir + velpatasvir) use compounds or mechanisms described in this patent family.
- Litigation and Challenges: Gilead’s patents have faced challenges and litigations, primarily concerning the scope of chemical claims and inventive step.
Patent Challenges and Expirations
- Patent challenges often focus on obviousness due to the close structural similarities to prior art compounds.
- Many patents in the space are expiring or nearing expiration, opening the market for generic development in 2032 or later.
Future Patent Strategies
- New formulations, combinations, or methods of administration remain avenues for extending patent exclusivity.
- Focus on pediatric formulations and tailored delivery methods.
Technical and Commercial Significance
- The patent’s claims cover a broad structural class of NS5A inhibitors that contributed to Gilead’s market dominance.
- Its scope encompasses compounds with improved pharmacokinetics, bioavailability, and resistance profiles.
- The patent’s broad claims serve as a blocking position against generic entry until expiration in 2032.
Key Takeaways
- US 8,372,828 claims a broad chemical space of NS5A inhibitors targeting HCV.
- Valid until 2032, with a comprehensive patent family supporting Gilead's antiviral portfolio.
- The patent landscape shows active patenting by competitors, but Gilead maintains a dominant position.
- The patent’s claims are narrow enough to allow design-around strategies, but its core compounds are fundamental to Gilead’s HCV franchise.
- Expiration in 2032 will open the market for generics, subject to patent challenges and legal strategies.
FAQs
1. Does the patent cover all NS5A inhibitors?
No, it specifically covers compounds within a defined chemical structure class, though it encompasses many relevant derivatives.
2. Are the claims broad or narrow?
The claims are broad in their chemical scope but are limited to the specific structures and substituents claimed.
3. Can competitors develop similar compounds?
Yes, through design-around strategies that avoid the patent’s chemical scope, but they must navigate existing patent claims and potential infringement.
4. Has the patent been challenged?
There is no publicly documented official challenge, but patentability and validity could be challenged closer to the expiration date, especially given prior art.
5. What is the expiration date for this patent?
Expected in 2032, assuming timely payment of maintenance fees and no legal challenges.
References
- United States Patent and Trademark Office. (2013). US 8,372,828 B2. Retrieved from https://patents.google.com/patent/US8372828B2
- Gilead Sciences, Inc. Patent Portfolio. (2022). Gilead’s patent family around HCV inhibitors.
- World Intellectual Property Organization. Patent landscape reports. (2021). Hepatitis C antiviral medications.
